Eloxx Pharmaceuticals, Inc. (ELOX) stock
Close on Nov 17, 2026Market cap $79.70MP/E –Yield –
Earnings
Eloxx Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Eloxx Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026during market hours | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023during market hours | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 16, 2023during market hours | – | – | -$2.88 | Release |
| Q4 FY2022ended Dec 31, 2022 | Apr 3, 2023before the open | – | – | -$2.92 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022during market hours | – | – | -$0.09 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022during market hours | – | – | -$0.12 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 4, 2022before the open | – | – | $0.14 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021before the open | – | – | -$0.11 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 17, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 7, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 11, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020during market hours | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 7, 2020during market hours | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 5, 2020during market hours | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 5, 2019during market hours | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 7, 2019before the open | – | – | – | Filing |
| Q1 FY2019ended Mar 31, 2019 | May 9, 2019before the open | – | – | – | Filing |
| Q4 FY2018ended Dec 31, 2018 | Mar 8, 2019before the open | – | – | – | Filing |
| Q3 FY2018ended Sep 30, 2018 | Nov 8, 2018before the open | – | – | – | Filing |
| Q2 FY2018ended Jun 30, 2018 | Aug 7, 2018during market hours | – | – | – | Filing |
| Q1 FY2018ended Mar 31, 2018 | May 10, 2018during market hours | – | – | – | Filing |
| Q1 FY2016ended Sep 30, 2015 | Oct 14, 2015during market hours | – | – | – | Filing |
| Q3 FY2015ended Mar 31, 2015 | May 15, 2015before the open | – | – | – | Filing |
| Q2 FY2015ended Dec 31, 2014 | Feb 19, 2015during market hours | – | – | – | Filing |
| Q1 FY2015ended Sep 30, 2014 | Nov 17, 2014before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Eloxx Pharmaceuticals has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Eloxx Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Eloxx Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- News
- Results
- Results
- News
- Results
- Update
- Update
- Results
- Update
- Results
- Results
See a number that looks wrong?